Concurring with our results, studies with liver, prostate, and lung cancers have reported that high expression of CKAP2L is associated with poor prognosis in tumor patients and can be used as a marker for diagnosis and treatment [13–15, 23]. Here, CKAP2L is linked to lung cancer.